SAGE-Hindawi Access Research
Enzyme Research
Volume 2011, Article ID 518258, 8 pages
doi:10.4061/2011/518258




Review Article
Trypanosome Prereplication Machinery: Potential New
Target Old Problem

          Simone Guedes Calderano, Patricia Diogo Melo Godoy,
          Julia Pinheiro Chagas da Cunha, Maria Carolina Elias
          LaboratÂ´orio Especial Toxinologia Aplicada (LETA) Center Applied Toxinology (CAT/CEPID),
          Instituto Butantan, Avenida Vital Brasil 1500, 05503-000 SËœao Paulo, SP, Brazil

          Correspondence addressed Maria Carolina Elias, carol@butantan.gov.br

          Received 15 December 2010; Revised 16 March 2011; Accepted 30 March 2011

          Academic Editor: Ariel M. Silber

          Copyright Â© 2011 Simone Guedes Calderano et al. open access article distributed Creative Commons
          Attribution License, permits unrestricted use, distribution, reproduction medium, provided original work           properly cited.

          Approximately million people suï¬€er Chagas disease worldwide, caused Trypanosoma cruzi, disease burden
          predominately focused Latin America. Sleeping sickness health problem, caused Trypanosoma brucei,
          especially sub-Saharan countries. Unfortunately, drugs currently available treat diseases toxic eï¬€ects           eï¬€ective disease phases parasite strains.  clear need development novel drugs drug
          targets treat diseases. propose trypanosome prereplication machinery component, Orc1/Cdc6, potential target
          drug development. trypanosomes, Orc1/Cdc6 involved nuclear DNA replication,  despite involvement           conserved process, Orc1/Cdc6 distinct mammalian Orc1 Cdc6 proteins.  RNAi-mediated silencing try-
          panosome Orc1/Cdc6 expression T. brucei decreased cell survival, indicating Orc1/Cdc6 critical trypanosome survival.


1. Introduction                                                           noninfective life cycle stage parasite prolifer-
                                                                          ate binary fission guts Triatoma infestans insects,
Currently, approximately million people Chagas                   commonly known kissing bugs. disease worldwide, disease burden centered              epimastigotes transform infective metacyclic
Latin America. 2008, approximately thousand people                 form insect hindgut.  insect vector
died disease. Sleeping sickness              bites mammalian host, eliminate metacyclic
health problem, particularly sub-Saharan countries;             parasites feces. allows parasites penetrate half twentieth century, disease practically             wounded skin enter mammalian hostâ€™s
decimated entire communities central Africa [1].                 circulatory  bloodstream, metacyclic surveillance programs, 2009 marked time                 parasites transform trypomastigotes, infect
50 years thousand new cases sleeping                mammalian cells transform amastigotes. Amastig-
sickness reported Africa (http://www org/).                   otes spherically shaped proliferate inside infected
     causal agents Chagas disease sleeping sickness            cells transforming nonreplicative trypomastigotes.  respectively, protozoan parasites Trypanosoma cruzi              life cycle completed insect vector bites T. brucei Kinetoplastida order. subspecies T.           infected mammalian host takes trypomastigotes
brucei, T. b. rhodesiense, T. b. gambiense, responsible           blood transform epimastigotes acute sleeping sickness Eastern Southern Africa                inside insect gut. chronic sleeping sickness Western Central                          contrast T. cruzi, life cycle T. brucei spp.
Africa, respectively. Chronic sleeping sickness accounts              entirely extracellular. case, infected tsetse
approximately 95  reported cases.                                  fly (Glossina genus) bites mammalian host, transferring
     protozoa life cycles alternate             metacyclic trypomastiogte forms circulatory sys-
mammalian host insect host. T. cruzi epimastigotes                 tem. Metacyclic trypomastiogtes transform bloodstream
 2                                                                                                                  Enzyme Research

trypomastigotes proliferate hemolymphatic           numerous eï¬€ects, benznidazole (BNZ) (N-benzyl-2- trypomastigotes, slender form;           nitroimidazole-1-acetamide) nifurtimox (NF) (4-([5- parasites transform non-proliferative form             nitrofurfuryledene]amino)-3-methylthiomorpholine-1,1 stumpy appearance. new tsetse fly bites              dioxide) eï¬€ective Chagas disease. infected mammalian host, non-proliferative, stumpy             introduced clinical use 1970â€™s [12]. NF
parasites taken fly transform                 increases production free radicals believed cause
proliferating procyclic forms fly midgut. Parasites           trypanosome death [13, 14], BNZ disrupts protein synthesis migrate salivary glands insect         respiratory chain T. cruzi  review [15]).
transform epimastigotes proliferate binary           drugs ineï¬€ective chronic phase
fission. Finally, epimastigotes transform infective         disease. phases Chagas disease, metacyclic trypomastigotes, injected           course treatment dependent patientâ€™s symptoms;
new mammalian host tsetse flyâ€™s bite.                     medicines surgery recommended patients      shown  Chagas disease transmitted           heart complications, diet changes possibly surgery infected feces triatomines, sleeping sickness         suggested patients digestive complications. transmitted infected saliva tsetse flies.               treat sleeping sickness, medicines currently  transmission modes shared                 commonly used. Pentamidine suramin considered
species, include transmission blood transfu-             stage drugs. Pentamidine used 1940 sions, vertical mother child transmission, acciden-        choice drug treat initial stages T. b.
tal infections laboratory.                                    gambiense infection; administered intramuscular
     Diagnosis based presentation clinical symp-        injection. exact antiprotozoal mechanisms action
toms signs, direct parasitological testing blood           pentamidine unknown, acts
cerebrospinal fluids  case T. brucei infection),           targets including mitochondria DNA
serological tests parasite DNA detection using             (reviewed [16, 17]). Suramin negative charges polymerase chain reactions (PCR). detect T. cruzi PCR,         allow interact electrostatically trypanosomal
samples assayed presence minicircle kinetoplast       enzymes, including enzymes involved glycolysis pen-
DNA 195-bp reiterated DNA sequence [2, 3].                 tose phosphate pathway [18]. resistance suramin
serological test used sleeping sickness diagnosis        observed T. b. gambiense, suramin currently card agglutination test trypanosomiasis (CATT);           used cases T. b. rhodesiense infection  review detects T. b. gambiense-specific antibodies [4]. Chagas       [16]).
disease, T. cruzi-specific antibodies detected                toxic pentamidine suramin, melarsoprol,
assays using crude recombinant antigens [5, 6].            eflornithine, combination eflornithine NF  use serological tests infer Chagas disease         melarsoprol-refractory patients) used treat
cure controversial, antibodies parasite antigens       patients neurological phase. Eflornithine, alpha-diflu- remain circulation long periods time [7].              oromethylornithine, administered intravenously      absence presence mild symptoms associated          infusion irreversible inhibits polyamine biosynthesis chronic phases diseases.  acute         acting ornithine decarboxylase (EC 4.1.1.17). symptoms Chagas disease diagnosed trained             eï¬€ective T. brucei gambiense infections [19]. spite
physician include swelling, nausea, diarrhea, vomiting,          toxic eï¬€ects, melarsoprol widely used
liver spleen enlargement, fever, headaches, chest          drug second stage sleeping sickness;  abdominal pain. 40  patients develop chronic                drug available treat T. b. rhodesiense infections.
disease heart colon dilation 10â€“20 years            Melarsoprol derived arsenic, believed infection. Similarly, sleeping sickness characterized     melarsen oxide active metabolite vivo. distinct stages. acute phase hemolymphatic             unknown melarsoprol kills parasites, parasite lysis
stage, symptoms include headache, malaise, weight loss,              following melarsoprol exposure demonstrated [20].
fatigue, fever, vomiting. second phase, known             clear need new drugs treat neurological phase, parasites present          trypanosome-induced diseases, drugs clinical tri-
cerebral spinal fluid brain cause neurological          als initiated recently. absence standard physiatric symptoms including anxiety, disruption         protocols evaluate drug eï¬ƒcacy absence sleep-wake cycle, behavior changes, motor features          clinical parasitological markers contribute diï¬ƒculty muscle tremors walking diï¬ƒculties [8]. untreated,          launching new treatment initiatives. case Chagas
sleeping sickness fatal. absence treatment,       disease, novel drugs toxic eï¬€ects shorter
estimated T. b. gambiense infection fatal       administration times drugs treat chronic disease
years [9] T. b. rhodesiense infection fatal   prioritized.  standard protocol drug months [10, 11].                                            screening acute T. cruzi infections proposed      Drugs used treat Chagas disease sleeping sickness        evaluate drug eï¬ƒcacy vitro vivo models undesired toxic eï¬€ects eï¬€ective        compared BNZ. important evaluate parasite life cycle stages parasite strains        eï¬€ect compounds chronic infection, drug resistance.  eï¬€ective drugs exist treat              possible diï¬ƒculty evaluating parasite acute phases diseases. Despite presence           clearance using current methods [21]. recently, studies
 Enzyme Research                                                                                                                    3
 focused azolic compounds itraconazole                   ORC1-6
                                                                                                   Orc1/Cdc6
posaconazole inhibit ergosterol synthesis. mouse
models, drugs shown cure acute chronic Chagas disease [22]. addition, posaconazole activity T. cruzi vivo vivo.
    Regarding sleeping sickness, new drugs lower toxic eï¬€ects, treat T. b. gambiense T. b.
rhodesiense infections, treat late-stage T. b. rhodesiense                    Cdc6
infection. Pafuramidine maleate (DB289) new drug clinical trial treatment sleeping sickness [23].   cross blood-brain barrier, used early stage treatment. Despite  advan-                                                           Unknow
                                                                                                                         protein
tage pentamidine orally administrated.                                                    (b)
                                                                                  Cdt1            MCM
    illustrated  need new drugs novel                               MCM
drug targets treat Chagas disease sleeping
sickness evident. drugs target fundamental
pathways parasites. spite conserved
nature essential pathways eukaryotic organisms,                    Mammals                   (B) Trypanosomatids identified trypanosome prereplication machinery com-
ponent fundamental replication distinct    Figure 1: Schematic representation prereplication machinery eukaryotic prereplication machinery; component           mammals   trypanosomatids (B).   (b) indicate
                                                                   possible mechanisms MCM recruitment repli- necessary origin selection establishment                                                                    cation origin.   Orc1/Cdc6 recruits MCM complex. (b) DNA replication fork [24]. data indicate       unknown protein recruits MCM complex replication
enzyme potential drug target treatment        origin.
Chagas disease sleeping sickness.

2. Eukaryotic Prereplication Machinery                             Orc1  Figure 2).  Orc1 closely related
                                                                   Cdc6 ORC component [30].
DNA replication eukaryotes begins assembly              ORC subunits, Orc1, Orc4, Orc5 belong prereplication complex regions chromosomes            AAA+ family, proteins exhibit ATPase activity
known replication origins [25, 26]. prereplication          function multiple cellular activities [31]. Orc2 complex assembly (depicted Figure 1) begins            Orc3 contain ATPase-like domain; Orc6 lacks AAA+
origin recognition complex (ORC), comprised diï¬€er-          domain shows structural similarity ent subunits (Orc1âˆ’6 ) [25, 27], recognizes replication        Orc proteins. AAA+ domain contains Walker origins allows recruitment cell division cycle          Walker B motifs regions named sensor 1 Cdc6 Cdt1 proteins complex.                sensor 2. regions typical proteins act ORC, Cdc6 Cdt1 proteins recruit mini-chromosome            â€œClamp-loadersâ€?, proteins encircle DNA bind maintenance (MCM) complex, comprised               factors serve processivity-promoting factors DNA
subunits (Mcm2âˆ’7 ); MCM complex harbors helicase           replication ATP-dependent manner. Walker B
activity essential DNA replication [28].      motifs sensor 1 2 regions responsible ATP
prereplication machinery bound replication origins,      binding hydrolysis [31]; ATP binding hydrolysis origins licensed, meaning replication           trigger conformational change ORC allows
process initiate origins binding       serial recruitment proteins prereplication
regulatory factors DNA replication fork components             complex assembly replication origins [32]. onset S-phase.                                           Cdc6 (58 KDa S. cerevisiae) isolated                                                                    thermo-sensitive mutants identified important
3. Structural Aspects ORC Cdc6                          factor beginning DNA replication [33]. Cdc6
   Prereplication Machinery Components                             AAA+ domain, containing Walker                                                                    Walker B motifs sensor 1 2 regions [30]. Similar ORC complex purified S. cerevisiae              Orc1, Cdc6 exhibits intrinsic ATPase activity vitro [34].
extract proteins bound replication origins [29]. S.
cerevisiae ORC (413 KDa) heterohexamer contains          4. Recruitment Prereplication Machinery proteins named according relative molecular mass:
Orc1 (120 KDa), Orc2 (72 KDa), Orc3 (62 KDa), Orc4                 molecular bases enable recruitment prerepli-
(56 KDa), Orc5 (53 KDa), Orc6 (50 KDa). Orc1âˆ’5                 cation machinery described yeast orthologs identified wide range organisms,            dependent ATP binding ATP hydrolysis (Figure 3).
suggesting genes present eukaryotic          mentioned previously, step prereplication
organisms. Orcs, Cdc6 notably similar        machinery assembly binding ORC  4                                                                                                                 Enzyme Research

                                                                                              Orc1Cdc6 tb
                                                                                              Orc1Cdc6 tc
                                                                                              Orc1Cdc6 lm
                                                                                              Cdc6 hs
                                                                                              Orc1 hs
                                                                                              Orc1Cdc6 mp
                                                                                              Orc3 hs
                                                                                              Orc5 hs
                                                                                              Orc2 hs
                                                                                              Orc4 hs
                                                                                              Orc6 hs
                                 506.9
                                     500     400        300         200        100        0
                                                     Aminoacids substitution              Ã—102


Figure 2: Phylogenetic tree human Orc1 Orc6, human Cdc6, Orc1/Cdc6 Trypanosoma cruzi (Orc1Cdc6 tc), Trypanosoma
brucei (Orc1Cdc6 tb), Leishmania major (Orc1Cdc6 lm), Methanoplanus petrolearius (orc1Cdc6 Mp), Archaea species. phylogenetic tree generated using ClustalW alignment method.



                 ATP                                                   occur [36].  ATPase activity ORC
                                                                       Cdc6 work select specific replication origins.
     ORC
                                                                           bound DNA, ORC Cdc6 able          âˆ—                   Specific                                  interact Cdt1, brings MCM complex                         replication origin                             replication origin. moment, low activity                                                                        Cdc6 ATPase important establish ORC-Cdc6-DNA
                                                                       interaction required recruit MCM complex
                                                                       replication origins (reviewed [37]). MCM
          âˆ—                                                            complex recruitment, Orc1 ATPase enables MCM-DNA
                 Cdc6                           ORC ATPase             interaction [38]. MCM complex recruited                                                  activity              established replication origins, ORC, Cdc6                                                                        Cdt1 need bound replication origin sites
                                                                       longer. point, prior activation DNA
                                                                       replication, proteins disassociate replication
               MCM
                                                                       origins ATPase-dependent manner [39].
                                                                           data clearly demonstrate extreme importance
                                                   ADP                 ATPase activities diï¬€erent components                         Cdt1
                                                                       prereplication machinery stabilization assembly                                                                        prereplication machinery DNA replication origins.
                               Cdc6 ATPase
                                 activity                              selection replication origins, assembly                                                                        prereplication complex replication origins, Figure 3: Schematic representation prereplication machinery         recruitment MCM helicase, dissociation
recruitment. Figure 3 shows Cdc6 ORC ATPase activities        prereplication complex replication origins important release molecules complex.     avoid new round DNA replication cell cycle,
Asterisks steps ORC ATPase activity (purple âˆ—)                                                                        balance high low ATPase activity critical
Cdc6 ATPase activity (orange âˆ—) important prevention assembly prereplication machinery nonspecific
                                                                       precise DNA replication.
replication origins.
                                                                       5. Trypanosome Orc1/Cdc6:                                                                           Prereplication Machinery Component
replication origins, step depends binding                ATPase Activity ORC ATP. ORC-double-stranded DNA interactions specific inhibit ATPase activity ORC.            eukaryotic cells, trypanosomes prereplica- way, high ATPase activity ORC inhibits stable          tion machinery component diï¬€erent eukary-
ORC interactions nonspecific DNA.                  otes instead closer Archaea species. Genomic
presence specific replication origin, ATPase activity         databases trypanosomatids organisms ORC inhibited, undergoes conformational             contain sequences genome code change; conformation change stabilizes ORC-DNA                 Orc1â€“Orc6 subunits, Cdc6 Cdt1. Additionally, interaction allows ORC bind Cdc6 (reviewed               Archaea sp. copies proteins [35]). stability ORC-Cdc6-DNA interactions              exhibit high sequence homology Orc1 Cdc6;
regulated ATPase activity Cdc6, high             proteins called Orc1/Cdc6 proteins [40â€“42] presence nonspecific DNA, destabilizing complex             (Figure 2). Trypanosomatids annotated gene [34]. ORC-Cdc6-DNA interactions trigger conformational               subunits ORC, Orc1, alteration Cdc6 allows Cdc6-Cdt1 interaction           homologous Cdc6. annotated Orc1 [43]  Enzyme Research                                                                                                                    5



                                  AAA+

                                                         WH




                                                                                    (b)

Figure 4:   Shows archaea Orc1/Cdc6 structure ATP. AAA+ WH domains indicated. (b) Shows predicted
structure T. cruzi Orc1/Cdc6, obtained using 3D-PSSM program (http://www.sbg.bio.ic.ac.uk/âˆ¼3dpssm/index2.html).



 named Orc1/Cdc6. TIGR Parasites Database               Orc1/Cdc6. Alternatively, prereplication machinery
(http://www.tigr.org/), sequences annotated             assembled unknown protein bind
Orc1 (Tc00.1047053511159.20 Tc1047053508239.10)              Orc1/Cdc6 recruit MCM complex replica- genome T. cruzi (representing gene alleles). Single          tion origins. assembly scheme depicted Figure 1(b).
sequences annotated Orc1 genomes T. brucei        important note studies confirm (Tb11.02.5110) T. brucei gambiense (Tbg972.11.8220).            schematic representation correct. Recently, group Orc1 protein sequences T. cruzi 98.2               Dr. Richard McCulloch identified identical. Orc1sequences T. cruzi T. brucei        ORC-like factor (pers comm.) T. brucei. studies
77.1  77.8  identical. Trypanosome Orc1/Cdc6                conducted determine Orc1/Cdc6 ATPase
confirmed prereplication machinery component           activity important assembly prereplication replaced yeast Cdc6 yeast phenotypic complementa-           machinery release prereplication
tion assay;  silencing trypanosome Orc1/Cdc6         complex proteins replication origins. 
expression RNA interference T. brucei impaired nuclear        silencing trypanosome Orc1/Cdc6 expression RNAi
DNA replication [24].                                               T. brucei negative aï¬€ected cell survival [24]. data
     Analyses structural alignment using Phyre server,     strongly indicates Orc1/Cdc6 extremely important web-based method protein folding recognition, showed            trypanosome survival identifies Orc1/Cdc6 potential higher structural similarity trypanosome Orc1/Cdc6             target drug design. archaea Orc1/Cdc6 [24].  analyses predicted
tridimensional structure T. cruzi Orc1/Cdc6 3D-               6. ATPase Activity Inhibitors
PSSM (http://www.sbg.bio.ic.ac.uk/âˆ¼3dpssm/index2.html), determines probable folds based               Diï¬€erent proteins harboring ATPase activity occurrence motifs present secondary structure,            studied potential drug targets inhibition showed probable structural T. cruzi Orc1/Cdc6           ATPase activity [46â€“49]. inhibition ATPase homologous Archaea Orc1/Cdc6 (Figure 4).                activity heat-shock protein 90 (HSP90) main target
analyses suggest trypanosome Orc1/Cdc6 closer            cancer treatment. HSP90 chaperone acts Archaea prereplication machinery mammalian pre-             folding, stabilization, assembly proteins replication machinery. Primary sequences trypanosome             involved biological processes [50, 51]; 
Orc1/Cdc6 contain Walker B motifs, related            responsible maintenance cancer cells ATP/GTP binding, sensor 1 2 regions                facilitating function oncoproteins allowing malignant
involved ATP hydrolysis; features typical           transformation [52]. HSP90 tumor cells prereplication machinery components exhibit AAA+           higher activity compared HSP90 normal cells
ATPase fold [44, 45]. fact, T. cruzi T. brucei          [53], inhibition eï¬€ects tumor cells higher Orc1/Cdc6 exhibit ATPase activity,  presence        normal cells [53], making HSP90 good target drug
increased concentrations ATP follows Michaelis-Menten          design [46, 54]. Geldanamycin, natural compound, (MM) kinetic model. ATPase activity increases           compound described antitumor eï¬€ects presence nonspecific DNA [24], suggesting  similar          inhibition HSP90 ATPase activity [55â€“57]. Geldanamycin yeast, trypanosome Orc1/Cdc6 ATPase activity               binds N-terminal ATP-binding pocket HSP90, involved selection specific replication origins.       blocking ATPase activity [58]. findings mentioned previously, Cdt1 homologous                reported, studies focused HSP90 protein trypanosomatid genome database.            target, drugs 17-DMGA (alvespimycin) organisms, prereplication machinery              17-AAG/tanespimycin reached phase phase II assembled recruitment MCM complex                  clinical trials, respectively [46].
 6                                                                                                                    Enzyme Research

    important health problem antibiotic resis-         References
tance treatment bacterial infections [59]. Diï¬€erent
proteins ATPase activity targeted high-         [1] J. Pepin, â€œCombination therapy sleeping sickness: wake-
                                                                       â€? Journal Infectious Diseases, vol. 195,  3, pp. 311â€“
throughput screening order new inhibitors                                                                        313, 2007.
potential antibiotic eï¬€ects. Bacterial RecA [60], DNA gyrase
                                                                   [2] G. Russomando, M. M. C. Tomassone,  Guillen et
[48], essential replicative DNA helicase [49]                                                                        al., â€œTreatment congenital chagasâ€™ disease diagnosed ATPase proteins eï¬€ort concentrated.            followed polymerase chain reaction,â€? American
RecA bacterial protein involved DNA repair,              Journal Tropical Medicine Hygiene, vol. 59,  3, pp.
interacts single-stranded DNA ATPase              487â€“491, 1998.
activity allows recombinational DNA repair            [3]  R. Vago, L. O. Andrade,   Leite et al., â€œGenetic
horizontal gene transfer, processes essential         characterization Trypanosoma cruzi directly tissues acquisition drug resistance genes [47]. Inhibitors RecA          patients chronic chagas disease: diï¬€erential distribution
ATPase activity act binding ATP-binding site               genetic types diverse organs,â€? American Journal screened, indicating potential development            Pathology, vol. 156,  5, pp. 1805â€“1809, 2000.
antibiotics capable preventing bacterial drug resistance        [4] E. Magnus, T. Vervoort, N. Van Meirvenne,  card-
[60].                                                                  agglutination test stained trypanosomes (C T.T.)     DNA gyrase replicative DNA helicase                    serological diagnosis T. b. gambiense trypanosomiasis,â€?
proteins involved bacterial DNA replication                 Annales la Societe Belge Medecine Tropicale, vol. 58,  3,
                                                                       pp. 169â€“176, 1978.
essential bacterial survival. ATPase activity
indispensable function [48]. DNA gyrase type        [5] E. S. Umezawa, S. F. Bastos, M. E. Camargo et al., â€œEvaluation
                                                                       recombinant antigens serodiagnosis Chagasâ€™ disease
II topoisomerase capable introducing negative supercoils
                                                                       South Central America,â€? Journal Clinical Microbiol- DNA replication. comprised                ogy, vol. 37,  5, pp. 1554â€“1560, 1999.
subunits  B), B subunit ATPase activity.                                                                    [6]  C. Pastini, S. R. Iglesias, V. C. Carricarte, M. E. Guerin, D. O.
aminocoumarin antibiotic class, novobiocin (4-              Sanchez,  C. Frasch, â€œImmunoassay recombinant
Hydroxy-3-[4-hydroxy-3-(3-methylbut-2-enyl)benzamido]-                 Trypanosoma cruzi antigens potentially useful screening
8-methylcoumarin-7-yl3-O-carbamoyl-5,5-di-C-methyl-                    donated blood diagnosing Chagas disease,â€? Clinical
Î±-l-lyxofuranoside) licensed treatment human                 Chemistry, vol. 40,  10, pp. 1893â€“1897, 1994.
infections, binds B subunit inhibiting ATP              [7] M. S. Leguizamon, Â´ G. Russomando,  Luquetti et al., â€œLong-
hydrolysis required DNA supercoiling preventing                lasting antibodies detected trans-sialidase inhibition
cell growth [48]. DNA replicative helicase, DNA B,              assay sera parasite-free, serologically cured chagasic
responsible opening double-stranded DNA ATP                patients,â€? Journal Infectious Diseases, vol. 175,  5, pp.
hydrolysis, makes DNA available replication           1272â€“1275, 1997.
machinery duplication bacterial genome.         [8]  J. Duggan M. P. Hutchinson, â€œSleeping sickness compounds, flavonoid myricetin triaminotriazine,               Europeans: review 109 cases,â€? Journal Tropical Medicine
able inhibit ATPase activity DNA B helicase               Hygiene, vol. 69,  6, pp. 124â€“131, 1966.
Escherichia coli Pseudomonas aeruginosa, respectively,         [9] F. Checchi, J.  N. Filipe, D. T. Haydon, D. Chandramohan,
preventing cell growth [49].  drugs                   F. Chappuis, â€œEstimates duration early exhibit cytotoxicity mammalian cell culture,            late stage gambiense sleeping sickness,â€? BMC Infectious
inhibitors screened possible drug candidates              Diseases, vol. 8, article 16, 2008.
[49].                                                             [10] M. Odiit, F. Kansiime, J. C. K. Enyaru, â€œDuration                                                                        symptoms case fatality sleeping sickness caused     discussed  inhibitors ATPase activity              Trypanosoma brucei rhodesiense Tororo, Uganda,â€? East studied possible drugs candidates;               African Medical Journal, vol. 74,  12, pp. 792â€“795, 1997.
novobiocin, used human treat-          [11] E. M. F`evre, P. G. Coleman, S. C. Welburn,  Maudlin,
ment. raises possibility searching specific         â€œReanalyzing 1900â€“1920 sleeping sickness epidemic hibitors T. brucei T. cruzi Orc1/Cdc6, proteins        Uganda,â€? Emerging Infectious Diseases, vol. 10,  4, pp. 567â€“ closely related protein humans.                       573, 2004.
                                                                  [12] J. C. P. Dias,  treatment Chagas disease (South
                                                                       American trypanosomiasis),â€? Annals Internal Medicine, vol.
7. Final Considerations                                                144,  10, pp. 772â€“774, 2006.
                                                                  [13] R. Docampo S. N. J. Moreno, â€œFree radical metabolism addition indispensable role DNA replica-                antiparasitic agents,â€? Federation Proceedings, vol. 45,  10,
tion initiator, ORC known aï¬€ect diverse cell                 pp. 2471â€“2476, 1986.
processes including chromosome segregation, cytokinesis,          [14] B. Enanga, M. R. Ariyanayagam, M. L. Stewart, M. P.
cell cycle regulation, gene expression [61].             Barrett, â€œActivity megazol, trypanocidal nitroimidazole,
time analyze trypanosome Orc1/Cdc6,                 associated DNA damage,â€? Antimicrobial Agents ATPase activity involved non-DNA replication               Chemotherapy, vol. 47,  10, pp. 3368â€“3370, 2003.
functions.  better justify additional eï¬€orts       [15] W. Apt, â€œCurrent developing therapeutic agents search ATPase inhibitor trypanosome                  treatment Chagas disease,â€? Drug design, development Orc1/Cdc6.                                                             therapy, vol. 4, pp. 243â€“253, 2010.
 Enzyme Research                                                                                                                              7

[16] M. P. Barrett, D. W. Boykin, R. Brun, R. R. Tidwell,            [34] C. Speck B. Stillman, â€œCdc6 ATPase activity regu-
     â€œHuman African trypanosomiasis: pharmacological                       lates ORCÂ·Cdc6 stability selection specific DNA
     engagement neglected disease,â€? British Journal                 sequences origins DNA replication,â€? Journal Biological
     Pharmacology, vol. 152,  8, pp. 1155â€“1171, 2007.                      Chemistry, vol. 282,  16, pp. 11705â€“11714, 2007.
[17] B. J. Berger, N. S. Carter,  H. Fairlamb, â€œPolyamine          [35] M. Lei B. K. Tye, â€œInitiating DNA synthesis:      pentamidine metabolism African trypanosomes,â€? Acta                recruiting activating MCM complex,â€? Journal Cell
     Tropica, vol. 54,  3-4, pp. 215â€“224, 1993.                            Science, vol. 114,  8, pp. 1447â€“1454, 2001.
[18] S. Hanau, M. Rippa, M. Bertelli, F. Dallocchio, M. P. Bar-      [36] S. Chen, M.  Vries, S. P. Bell, â€œOrc6 required
     rett, â€œ6-Phosphogluconate dehydrogenase Trypanosoma                 dynamic recruitment Cdt1 repeated Mcm2âˆ’âˆ’7
     brucei. Kinetic analysis inhibition trypanocidal drugs,â€?          loading,â€? Genes Development, vol. 21,  22, pp. 2897â€“
     European Journal Biochemistry, vol. 240,  3, pp. 592â€“599,          2907, 2007.
     1996.                                                               [37] C. Evrin, P. Clarke, J. Zech et al.,  double-hexameric
[19] C. Burri R. Brun, â€œEflornithine treatment                 MCM2-7 complex loaded origin DNA licensing
     human African trypanosomiasis,â€? Parasitology Research, vol.              eukaryotic DNA replication,â€? Proceedings National
     90,  1, pp. S49â€“S52, 2003.                                            Academy Sciences United States America, vol. 106,
[20] S. R. Meshnick, R. W. Grady, S. H. Blobstein,  Cerami,              48, pp. 20240â€“20245, 2010.
     â€œPorphyrin-induced lysis Trypanosoma brucei: role          [38] J. C. W. Randell, J. L. Bowers, H. K. RodrÂ´Ä±guez, S. P. Bell,
     zinc,â€? Journal Pharmacology Experimental Therapeutics,            â€œSequential ATP hydrolysis Cdc6 ORC directs loading
     vol. 207,  3, pp. 1041â€“1050, 1978.                                    Mcm2âˆ’7 helicase,â€? Molecular Cell, vol. 21,  1, pp. 29â€“
[21]  J. Romanha, S. L. Castro, M. N. C. Soeiro et al.,               39, 2006.
     vitro vivo experimental models drug screening            [39] V. Tsakraklides S. P. Bell, â€œDynamics pre-replicative
     development Chagas disease,â€? Memorias Instituto               complex assembly,â€? Journal Biological Chemistry, vol. 22, pp.
     Oswaldo Cruz, vol. 105,  2, pp. 233â€“238, 2010.                        877â€“884, 2010.
[22]  Liendo, K. Lazardi, J.  Urbina,  vitro antiprolifera-
                                                                         [40] M. Felice, L. Esposito, B. Pucci et al., â€œModular organiza-
     tive eï¬€ects mechanism action bis-triazole D0870
                                                                              tion Cdc6-like protein crenarchaeon Sulfolobus
     $(-) enantiomer Trypanosoma cruzi,â€? Journal                                                                               solfataricus,â€? Biochemical Journal, vol. 381,  3, pp. 645â€“653,
     Antimicrobial Chemotherapy, vol. 41,  2, pp. 197â€“205, 1998.
                                                                              2004.
[23] J. H. Ansede, M. Anbazhagan, R. Brun, J. D. Easterbrook, J.
                                                                         [41] M. Felice, L. Esposito, B. Pucci, M. Falco, M. Rossi,      E. Hall, D. W. Boykin, â€œO-alkoxyamidine prodrugs                                                                               F. M. Pisani,  CDC6-like factor archaea Sulfolobus
     furamidine: vitro transport microsomal metabolism                                                                               solfataricus promotes binding mini-chromosome main-
     indicators vivo eï¬ƒcacy mouse model Trypanosoma
                                                                              tenance complex DNA,â€? Journal Biological Chemistry, vol.
     brucei rhodesiense infection,â€? Journal Medicinal Chemistry,
                                                                              279,  41, pp. 43008â€“43012, 2004.
     vol. 47,  17, pp. 4335â€“4338, 2004.
[24] P. D. Melo Godoy, L.  Nogueira-Junior, L. S. Paes et           [42] M. Felice, L. Esposito, M. Rossi, F. M. Pisani, â€œBio-
     al., â€œTrypanosome prereplication machinery contains single             chemical characterization Cdc6/ORC1-like proteins
     functional Orc1/Cdc6 protein, typical archaea,â€?              crenarchaeon Sulfolobus solfataricus,â€? Extremophiles,
     Eukaryotic Cell, vol. 8,  10, pp. 1592â€“1603, 2009.                    vol. 10,  1, pp. 61â€“70, 2006.
[25] S. P. Bell  Dutta, â€œDNA replication eukaryotic cells,â€?     [43] N. M. El-Sayed, P. J. Myler, D. C. Bartholomeu et al.,       Annual Review Biochemistry, vol. 71, pp. 333â€“374, 2002.               genome sequence Trypanosoma cruzi, etiologic agent [26] B. Stillman, â€œOrigin recognition chromosome cycle,â€?              chagas disease,â€? Science, vol. 309,  5733, pp. 409â€“415, 2005.
     FEBS Letters, vol. 579,  4, pp. 877â€“884, 2005.                   [44] J. E. Walker, M. Saraste, M. J. Runswick, N. J. Gay,
[27] J. F. X. Diï¬„ey, â€œDNA replication: building perfect switch,â€?          â€œDistantly related sequences alpha- beta-subunits
     Current Biology, vol. 11,  9, pp. R36